Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV

Hennion & Walsh Asset Management Inc. bought a new stake in Indivior PLC (NASDAQ:INDV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 360,245 shares of the company’s stock, valued at approximately $14,781,000. Hennion & Walsh Asset Management Inc. owned approximately 0.30% of Indivior as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after purchasing an additional 700 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in shares of Indivior during the fourth quarter worth $30,000. Quarry LP acquired a new position in shares of Indivior during the third quarter worth $26,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior News Summary

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright raised its Indivior earnings forecasts across 2026–2030. The firm lifted its 2026 EPS estimate to $3.66 from $3.08, raised 2027 EPS to $3.83 from $3.34, and increased 2028–2030 estimates to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates also rose to $0.93 for Q3 2026 and $1.07 for Q4, signaling improved expectations for the company’s operating performance. Indivior analyst estimates
• Positive Sentiment: An insider purchased additional shares. Chief Accounting Officer Woodrow Anderson bought 1,500 shares at an average price of $36.28, increasing his direct holdings by 6.09%. Insider buying can be viewed as a modest vote of confidence in the stock’s valuation and outlook. Insider Buying: Indivior CAO Acquires 1,500 Shares
• Neutral Sentiment: Analyst sentiment remains favorable but not uniformly bullish. Indivior has a consensus “Moderate Buy” rating and an average price target of $45.17, while individual recommendations include a $53.00 buy target from Craig Hallum and a reduced—but still “overweight”—$43.00 target from Barclays. Indivior receives Moderate Buy rating
• Negative Sentiment: A law firm is investigating the proposed Supernus acquisition. Kahn Swick & Foti is reviewing whether the transaction’s price and sale process adequately protect Supernus shareholders. Under the proposed deal, Supernus investors would receive 1.5401 Indivior shares per Supernus share. The investigation may add legal and execution uncertainty to the transaction and could raise concerns about potential share issuance and dilution for Indivior investors. Supernus Pharmaceuticals investor alert

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Barclays cut their price target on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 24th. Finally, Craig Hallum reissued a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.17.

Insider Transactions at Indivior

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of Indivior stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the transaction, the insider owned 209,337 shares of the company’s stock, valued at $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of Indivior stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares in the company, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Indivior Price Performance

NASDAQ INDV opened at $38.82 on Friday. The firm’s fifty day moving average price is $39.28 and its 200 day moving average price is $35.64. Indivior PLC has a 12 month low of $21.83 and a 12 month high of $42.81. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of 13.91 and a beta of 0.86.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The firm had revenue of $343.00 million during the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. As a group, sell-side analysts forecast that Indivior PLC will post 3.66 earnings per share for the current year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.